Archives
-
IGFBP2–THBS1 Mechanism in GH-Treated ISS
2026-08-19
The reference study identifies an IGFBP2–THBS1 regulatory axis that links growth hormone treatment to IGF-1 signaling, chondrocyte proliferation, and hypertrophic differentiation in idiopathic short stature. Its perturbation experiments suggest that IGFBP2 is more than a biomarker: it is a functional mediator that may help explain variable responses to somatotropin therapy and guide future mechanistic studies.
-
HyperScript First-Strand cDNA Synthesis Kit for Stress RNA
2026-08-19
Convert structurally challenging or scarce plant RNA into cDNA suited for PCR amplification and qPCR reaction workflows. The HyperScript First-Strand cDNA Synthesis Kit combines primer flexibility with a thermally stable, RNase H-reduced reverse transcriptase for transcriptomics validation and low-copy gene reverse transcription.
-
Biotin-tyramide: Practical TSA Workflows
2026-08-18
Biotin-tyramide converts target-bound HRP into a localized amplification engine for demanding IHC and ISH assays. This guide connects reagent handling, assay controls, and troubleshooting with the spatial-RNA perspective of Halo-seq, while clearly separating compatible imaging workflows from non-interchangeable transcriptome methods.
-
ATP Solution for mRNA and Kinase Workflows
2026-08-18
A ready-to-use 100 mM ATP reagent supports reproducible in vitro transcription, kinase, ligation, and phosphorylation workflows. This practical guide connects ATP-dependent assay control with p21 mRNA–LNP research while separating validated study findings from recommended optimization conditions.
-
Cabozantinib Blocks MLKL Oligomerization in Psoriasis
2026-08-17
The reference study identifies cabozantinib as a repurposed inhibitor of necroptosis that acts at the MLKL oligomerization stage rather than primarily blocking upstream RIPK1 or RIPK3 signaling. In an imiquimod-induced psoriasis model, this mechanism was associated with reduced epidermal hyperplasia and inflammatory cytokine expression, providing a rationale for mechanism-guided drug repositioning screening in inflammatory disease.
-
DAMGO: µ-Opioid Receptor Agonist Workflows
2026-08-17
DAMGO enables controlled interrogation of µ-opioid receptor signaling from membrane assays to central pain circuits. This workflow-oriented guide shows how to connect receptor activation, mechanical hypersensitivity, and tolerance models while avoiding common interpretation and handling errors.
-
Bleomycin Sulfate: From DNA Breaks to Fibrosis
2026-08-16
Bleomycin Sulfate, also recognized in clinical literature as Blenoxane, is more than a DNA-damaging compound. Its metal-dependent oxidative chemistry creates a translational bridge between oncology, pulmonary fibrosis research, and emerging studies of tissue-specific fibrotic signaling.
-
KDM4D–Foxo1 Control of MSC Quiescence
2026-08-15
The 2024 reference study identifies an iron-sensitive KDM4D–PIK3R3–PI3K–Akt–Foxo1 pathway that controls the transition of bone marrow mesenchymal stem cells from quiescence to activation. Its findings connect impaired histone demethylation during iron deficiency with defective MSC mobilization and reduced bone mass, while pathway modulation partially reverses the skeletal phenotype.
-
IWP-2: A Wnt Production Inhibitor for Cell Workflows
2026-08-14
IWP-2 is a potent Wnt production inhibitor for separating ligand-dependent Wnt biology from downstream pathway effects. This guide translates its use across gastric cancer assays and the 6C corneal epithelial culture paradigm, with practical formulation, dosing, readout, and troubleshooting strategies.
-
Brain–Spinal Control of Opioid Hypersensitivity
2026-08-14
Yin et al. identify a lateral parabrachial-to-hypothalamic-to-spinal pathway that controls morphine-induced mechanical hypersensitivity and analgesic tolerance in mice. The study shows that opioid activation can disrupt spinal gate control for mechanically evoked pain, offering a circuit-level explanation for paradoxical pain sensitization during repeated opioid exposure.
-
IEM-1925 in Soman-Induced Status Epilepticus
2026-08-13
A rat study evaluated IEM-1925, a dual AMPA/NMDA glutamate receptor antagonist, against soman-induced status epilepticus and its neurological consequences. The compound reduced seizure burden, improved survival, limited hippocampal injury, and alleviated anxiety-like and cognitive abnormalities more consistently than diazepam in the reported model.
-
N1-Methylpseudo-UTP: RNA Synthesis Guide
2026-08-13
N1-Methyl-Pseudouridine-5'-Triphosphate is a modified uridine triphosphate substrate for producing N1-methylpseudouridine-containing RNA by in vitro transcription. Peer-reviewed evidence indicates that this modification supports accurate translation without significantly changing ribosomal decoding or stabilizing mismatched RNA duplexes (https://doi.org/10.1016/j.celrep.2022.111300).
-
Cyclo (-RGDfC): αvβ3 Integrin Research Guide
2026-08-12
Cyclo (-RGDfC) is the cyclic RGD peptide c(RGDfC) for αvβ3 integrin research. Its defined structure, DMSO solubility, and reported approximately 98% purity support controlled studies of tumor targeting, angiogenesis research, and integrin-mediated cell adhesion.
-
Cefodizime: Applied Assays and Workflow Guide
2026-08-12
Cefodizime provides a practical third-generation cephalosporin antibiotic platform for susceptibility testing, resistance profiling, and host–pathogen experiments. This guide translates comparative MIC methods into reproducible workflows while defining important boundaries, including weak activity against Pseudomonas aeruginosa, ESBL-producing isolates, and MRSA.
-
Dorsomorphin (Compound C): AMPK and BMP Inhibitor
2026-08-11
Dorsomorphin, also called Compound C, is a cell-permeable, reversible ATP-competitive inhibitor used to interrogate AMPK and BMP signaling. Its dual pathway activity can alter ACC phosphorylation, autophagic proteolysis, Smad1/5/8 phosphorylation, iron metabolism, and differentiation outcomes, so pathway-specific controls are essential.